NPM1
EstablishedNPM1 mutation is the most common AML genetic abnormality and, in isolation, one of the most favorable prognostic markers.
NPM1 is the single most commonly mutated gene in AML, and on its own, it's actually a good sign for how a patient's leukemia is likely to behave. But when a second, less favorable mutation is also present, the outlook changes considerably — which is why doctors always look at these mutations together, not in isolation.
NPM1 (nucleophosmin 1) is a nucleolar protein involved in ribosome biogenesis and tumor suppressor regulation; mutations causing abnormal cytoplasmic localization of the protein are the single most common genetic abnormality in acute myeloid leukemia, found in roughly 30% of adult AML cases.
NPM1-mutated AML (without co-occurring adverse mutations) is classified as favorable risk under both 2022 and 2024 ELN criteria, with the longest reported overall survival (39 months in one analysis) among the major AML genetic subgroups when signaling gene mutations (FLT3-ITD, KRAS, NRAS) are absent.
Detected via PCR or NGS panel on bone marrow or blood; NPM1 mutation status is now incorporated into the World Health Organization's formal AML classification as a distinct disease entity ("AML with mutated NPM1"), reflecting its central role in both diagnosis and prognosis.
NPM1 mutation status, considered together with FLT3-ITD co-mutation status, meaningfully changes treatment intensity decisions — isolated NPM1 mutation supports a more favorable treatment approach, while co-occurring FLT3-ITD or other signaling mutations shifts management toward more intensive therapy or transplant consideration given the substantially worse prognosis.
Now incorporated as a distinct WHO AML disease entity; prognosis depends heavily on co-occurring mutations, especially FLT3-ITD.
- Blood. (2024). Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.